Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 + 2906 word(s) 2906 2021-07-12 06:16:23 |
2 format correction Meta information modification 2906 2021-07-23 06:12:27 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Somoza, �.; Prajapati, R. Albumin Nanostructures in Cancer. Encyclopedia. Available online: (accessed on 06 December 2023).
Somoza �, Prajapati R. Albumin Nanostructures in Cancer. Encyclopedia. Available at: Accessed December 06, 2023.
Somoza, Álvaro, Rama Prajapati. "Albumin Nanostructures in Cancer" Encyclopedia, (accessed December 06, 2023).
Somoza, �., & Prajapati, R.(2021, July 23). Albumin Nanostructures in Cancer. In Encyclopedia.
Somoza, Álvaro and Rama Prajapati. "Albumin Nanostructures in Cancer." Encyclopedia. Web. 23 July, 2021.
Albumin Nanostructures in Cancer

Albumin is a versatile protein being used widely for developing carriers for drugs and nucleic acids. It provides biocompatibility, tumor specificity, the possibility for surface modification, and reduces toxicity. 

albumin gene therapy cancer nanocarriers surface modification

1. Introduction

Cancer is one of the major public health problems and a leading cause of morbidity and mortality worldwide [1][2]. According to the data presented in Cancer Statistics, 2020, the 5-year relative survival rate for all cancers diagnosed from 2009 to 2015 was 67% [2]. Despite being one of the major causes of death, early tumor diagnosis and efficient therapy are still a challenge. The current cancer therapy includes surgical intervention, radiation therapy, and chemotherapy with the aim of tumor shrinking and cancer relapse reduction. However, chemotherapy is often associated with side effects caused by the off-site toxicity due to the lack of drug specificity [3]. Therefore, the design of more efficient therapies with improved selectivity to the tumor sites is desired.
Currently, gene therapy in cancer is gaining increasing scientific and clinical interest because of various revelations regarding the origin of cancers from genetic errors, either environmentally triggered or hereditary. Gene therapy is aimed at treating or repairing the errors occurring in tumor suppressor genes, oncogenes, or DNA pathways by substitution or addition of a functional gene into the living cell [4]. However, its success is challenged by the high molecular weight, enzymatic degradation, and anionic nature of nucleic acids [5][6]. In this regard, nanostructures are gaining increasing popularity as nucleic acids delivery vehicles due to low off-target effects, improvement of current therapies, and protection of nucleic acids from enzymatic degradation [7][8]. By modulating the chemical and physical properties of nanostructures, their biological characteristics, including cellular uptake, toxicity, immunogenicity, and efficacy, can be regulated [7][9]. Moreover, nanostructures can be accumulated in the tumor sites due to leaky vessels caused by rapid and excessive angiogenesis, commonly known as the enhanced permeability and retention (EPR) effect [10]. In addition to passive targeting by the EPR effect, active targeting can be achieved through the use of different targeting moieties, such as antibodies, aptamers, or small molecules that interact with great selectivity with selected receptors in the cell surface [11][12][13].
In the case of the application of gene therapy in cancer, nanocarriers based on polymers, lipids, and metals are widely being investigated. However, their clinical application is limited because of their toxicity, scale-up complications, and immunogenicity [9]. In this regard, protein-based nanocarriers have shown promising use in cancer because of their unique features such as biocompatibility, safety, tumor targeting by surface modification, ease of preparation, and broad stability profiles.

2. Nucleic Acids in Cancer Therapy

Gene therapy considers the molecular basis of the diseases and refers to the transfer of genetic material into cells with the aim of a therapeutic response. The first human in-vivo gene transfer study was conducted by Rosenberg and co-workers in 1990 in patients with advanced melanoma [14]. The study showed the feasibility, safety, and potency of using gene therapy in humans. This finding has revolutionized the field of gene therapy and from the last two decades, multiple approaches have confirmed the potential of nucleic acids for the treatment of various types of cancer [15][16]. The most widely used nucleic acids for cancer therapy include small interfering RNA (siRNA), antisense oligonucleotides (ASOs), aptamers, micro RNAs (miRNA), and plasmid DNA (pDNA) [17][18]. Their mechanism of action varies widely, ranging from mRNA regulation to protein binding, which can be designed to promote the reduction in cancer cell proliferation, induction of apoptosis, enhancement of immune-stimulatory responses, and inhibition of neoangiogenesis [19][20][21]. The small RNAs form an RNA-induced silencing complex (RISC), which in turn silences the mRNA translation, whereas ASOs can act either by suppression of the ribonucleoprotein activity or by activation of the enzymatic cascade that enhances mRNA degradation [22]. The great therapeutic potential of nucleic acids has been assessed in multiple experiments in cell culture or animal models [23][24]. However, some challenges need to be addressed to ease their path to the clinic.

3. Albumin-Based Nanocarriers

3.1. Albumin

Albumin, with a molecular weight of around 67 kDa is the most abundant protein in human blood, which is synthesized in the liver and has a circulation half-life of approximately 19 days [25]. Albumin has an overall negatively charged surface, which makes it highly water-soluble [26]. It has various ligand binding sites, namely Sudlow’s site I, which mainly binds the dicarboxylic acids and bulky heterocyclic molecules and, Sudlow´s site II (indole-benzodiazepine site), which has an affinity towards the aromatic carboxylic acids [27]. The high stability of albumin is attributed to the disulfide bonds formed internally by 34 cysteine residues [28]. In addition, it has one free cysteine residue on the outer surface, which is responsible for the conjugation of ligands [25][28]. Albumin transcytosis is mediated by various receptors such as GP60, also known as albondin, SPARC, also known as osteonectin, GP18, and GP30. GP18 and GP30 receptors are mostly responsible for the lysosomal degradation of deleterious albumin since these receptors have an affinity to the modified albumin such as oxidized or glycated ones [25][29]. The unique properties of albumin, including long half-life, the ability of cellular receptor-mediated transcytosis, and surface properties aiding in the conjugation of other moieties, make it a suitable candidate for the preparation of nanocarriers. In this sense, the most commonly used albumins include ovalbumin, bovine serum albumin (BSA), and human serum albumin (HSA) [30]. Among them, BSA is most widely accepted because of its low cost, abundance, and ease of purification, whereas HSA is used to avoid any immunological response in studies involving humans [30].

3.2. Albumin in Cancer Therapy

Albumin is being investigated extensively in cancer therapy due to its excellent properties as a selective carrier in this type of disease. This is due to many factors that lead to a preferable accumulation of the albumin structures in the tumor. For instance, the high concentration of albumin in the blood (40 mg/mL) compared to the interstitial concentration of 14 mg/mL aids in the diffusional transport of albumin to tumor sites [31][32]. In addition, albumin is preferentially internalized as the source of amino acids to cope with the enhanced cellular growth by the cancer cells expressing oncogenic Ras, whose activation is associated with cancer [26]. This property can be utilized to deliver the cargo encapsulated in albumin to cancer cells. Moreover, the albumin-binding proteins, namely gp60 and SPARC, are overexpressed in the cancer cells, which provides specificity to targeting the tumor sites [33]. The protein Cav-1 responsible for the formation of caveolae is upregulated in cancer cells, and since endocytosis of albumin is mainly mediated through caveolae, the accumulation of albumin in cancer sites is further enhanced [26][34]. Albumin is hence being used in pharmaceutical applications as a biocompatible and biodegradable carrier for the delivery of anti-cancer agents, such as chemotherapeutics, biologics, and immunomodulatory drugs. So far, the most studied albumin-based delivery systems for nucleic acids are nanoparticles, nanoconjugates and polyplexes (Figure 1).
Figure 1. Schematic representation of different albumin nanocarriers for gene therapy.

3.3. Albumin Nanocarrier for Gene Therapy in Cancer

In comparison to other nanocarriers, albumin-based nanocarriers provide various advantages including easy and reproducible production, possible scale-up options, and in addition, do not show undesired interaction with the serum [35][36]. Considering those advantages and its success in the delivery of chemotherapeutic agents, serum albumin can also be utilized for the delivery of nucleic acids. A wide range of studies on albumin nanocarriers has been conducted to efficiently deliver various genetic materials to the tumor sites (Table 1). In addition, albumin-based nanocarriers are finding their promising application in cancer immunotherapy in recent years.
Table 1. List of albumin-based nanocarriers with nucleic acids for cancer therapy.

Therapeutic Nucleic Acid

Type of Nanocarrier

Size (nm)

Z-Potential (mV)

Model System






−15.4 (pH 7)

+11.3 (pH 2)

BALB/c mice bearing i.c. C6 gliomas (Brain Tumor [23])

Plasmid pCMV-EGFP-C

PEI Polyplex



HeLa cells [37]

hMDA-7 plasmid




PANC-1 and BXPC-3 human pancreatic cell lines and tumor-induced BALB/c nude mice [24]

pGL3 vector coding for the firefly luciferase gene


300 to 700

−7 in H2O

+16 in 1 mM KCl

Human epithelial kidney 293-cells [38]






Tumor spheroids of A375/GFP cells [39]

Antisense Oligonucleotides (ASOs)




MCF-7 cells [40]

Akt1 ASOs

Lipid-HSA NPs



KB cells and A549 cells [41]



Self-crosslinked HSA NPs



B16F10 murine melanoma cells, squamous cell carcinoma cells (SCC7), and human prostatic carcinoma cells (PC-3) [42]

Bcl-2-specific siRNA

Anti-ErbB-2 antibody conjugated BSA nanocomplex



SK-BR-3 and MCF-7 breast cancer cells [43]

phrGFP-targeted siRNA

HSA-coated lipid NPs



MCF-7, MDA-MB-231, SK-BR-3 cells, and phrGFP-transfected MCF-7 xenograft tumor mice model [44]

Immunotherapeutic biologics

Vaccine conjugated with Evans blue (EB) and CpG

Albumin/vaccine nanocomplexes



Female C57BL/6 mice s.c. inoculated with EL4 cells, or EG7.OVA cells, B16F10 cells, MC38 cells on the shoulder [45]

PD-L1 plasmid (CRISPR/Cas9)

Stearyl PEI complexed HSA NPs



Mouse colon carcinoma CT26 cells [46]

BSA NPs = Bovine Serum Albumin Nanoparticles; HAS = Human Serum Albumin; VEGF = Vascular Endothelial Growth Factor; CRISPR = Clustered, Regularly Interspaced, Short Palindromic Repeat.

3.4. Albumin Nanoparticles

One of the most widely used methods of utilizing albumins (e.g., BSA, HSA) as a carrier for nucleic acids in cancer therapy is by encapsulation of the desired nucleic acids into albumin-based nanoparticles [47]. These structures can be prepared by various techniques, including desolvation, thermal gelation, emulsification, nanospray drying, and self-assembly. Among all those methods, desolvation is the most practiced method using ethanol as a desolvating agent and glutaraldehyde as a cross-linker [16][48][49]. The albumin nanoparticles protect the integrity of encapsulated nucleic acids and prevent their enzymatic degradation. They enter the cells via an energy-dependent mechanism, primarily through caveolae- and clathrin-mediated endocytotic pathways [48]. Albumin nanoparticles have been employed to deliver different nucleic acids, such as plasmids, oligonucleotides, and siRNAs.

3.5. Polyplexes

Another type of nanostructure based on albumin employed in the delivery of nucleic acids are polyplexes. These structures contain positively charged polymers that interact with the negatively charged nucleic acids, inducing their condensation into smaller structures. The formation of this complex protects the nucleic acids against degradation by nucleases and also increases their internalization, since the positive charges present in the surface of the nanoparticle interact with the negatively charged cell membranes [50][51]. Despite the excellent properties reported for the transfection of nucleic acids, they present some toxicity, which has motivated the search for complementary transfection systems or additives to mitigate this drawback. In this regard, several studies have reported that albumin can enhance the transfection efficiency of polyplexes and improve cell viability [37][52].
For instance, in a study conducted by Syga and co-workers, the use of albumin in a PEI-pDNA polyplex accelerated and enhanced the transfection in HeLa cells [37]. They prepared two types of polyplexes, Type 1, where BSA was placed between the plasmid pGFP and PEI, and Type 2 where albumin was added at the end, on the surface of previously formed polyplexes (PEI + pGFP). The experiments revealed that transfection efficiency was better with Type 1 polyplexes as the release of plasmid was easier from the loosely formed polyplexes compared to the Type 2 polyplexes with strong interaction between PEI and plasmid. Similarly, in a study conducted by Nicoli and co-workers, enhancement in cellular uptake was observed in metastatic breast cancer epithelial cells when HSA was incorporated in branched polyethylenimine (bPEI)-siRNA polyplexes [53].

3.6. Nanoconjugates

Albumin nanoconjugates are obtained by the interaction of albumin with other moieties such as polymers, nucleic acids, or metals. The interaction may be either non-covalent (hydrophobic and electrostatic) or covalent (thiol-maleimide coupling, Michael addition reaction, and carbodiimide coupling reactions) [54]. Nanoconjugates are smaller (~10 nm) than the typical nanoparticles (~100 nm) and can overcome the limitations associated with the nanoparticles, such as limited biodistribution and toxicity [55]. However, these small conjugates are rapidly metabolized, excreted in vivo, and less effective in exploiting the EPR effect to reach the tumor sites than conventional nanoparticles [56].
In a study conducted by Carver and co-workers, HSA nanoconjugates with RGD-623 oligonucleotides having a size of about 13 nm were prepared [57]. Interestingly, the resulting HSA-RGD-623 conjugate could penetrate a 3D tumor spheroid, whereas the conventional nanoparticles could deliver their payload only on the exterior cells of the spheroid, limiting the induction of splice correction of both GFP654 and Luc705 reporter genes. Similarly, in a study by Sarett and co-workers, serum albumin was used as a carrier in vivo for siRNAs modified with a diacyl lipid moiety (siRNA-L2), which enhanced the pharmacokinetic properties of siRNA. This nanoconjugate showed 19-fold more tumor accumulation and 46-fold cellular uptake compared to the commercial siRNA nanocarrier jetPEI, in a mouse orthotopic model of human triple-negative breast cancer [58]. Despite the various advantages of modifying the nucleic acids to increase the stability, pharmacokinetics and pharmacodynamic properties, and enhancement of internalization and endosomal escape, limited work has been done using albumin nanocarriers [59]. Further studies integrating the advantages of albumin nanocarriers with the modified nucleic acids can be of great potential in cancer therapy.

4. Albumin as a Coating Agent

Besides its use as a nanocarrier, albumin can be used as a coating agent for a variety of nanostructures, thus the advantages mentioned before on the use of albumin can be implemented to other nanostructures [44][60][61]. In a study conducted by Xu and co-workers, a chitosan complex with siRNAs was coated with pH-responsive detachable BSA to enhance recognition by human hepatocellular carcinoma cells and suppression of tumor cell proliferation [61]. In this case, the mRNA silencing obtained by the chitosan NPs was improved from 46.9% to 61.8% by the introduction of a BSA coating.
Albumin has been used as a coating agent in various lipid-based nanocarriers, to minimize their interaction with serum proteins and improve their delivery to the target sites [44][62]. For instance, HSA was used to coat lipid nanoparticles loaded with siRNA targeted against GFP (HSA-LNPs-siRNA) and their activity was evaluated in breast cancer cells and the corresponding xenograft mouse model [44]. In the cell experiments, the nanoparticles containing HSA significantly reduced the GFP fluorescence, compared to uncoated lipid nanoparticles. This result was also obtained in the animal model, where a 37% reduction in the GFP expression was achieved after systemic administration of the HSA-coated nanoparticles. In another study, HSA was employed to coat lipid nanoparticles loaded with an antisense oligonucleotide against Bcl-2, which were evaluated in KB human oral carcinoma cells [62]. Interestingly, the authors reported that the efficiency of the Bcl-2 down-regulation depended on the molar ratio of HSA employed. The optimum down-regulation was observed with an HSA to liposome ratio of 3:100 after which the increment in HSA decreased the efficiency.

5. Nucleic Acid-Loaded Albumin Nanocarriers for Immunotherapy

Cancer immunotherapy aims to exploit the patients’ own immune systems to treat cancer. Some of the approaches to cancer immunotherapy include immune checkpoint blockade, cancer vaccines, adoptive cell transfer therapy, and oncolytic virotherapy [63]. Among all, immune checkpoint inhibitors have gained wide success in cancer treatment, however, only a limited number of patients benefit from these therapies, where the induction of resistance and toxicity are still huge problems [64]. Interestingly, nucleic acid therapeutics are emerging as the potential candidate for cancer immunotherapy, which may improve the therapeutic outcome in a wide range of tumors, and even in the late stages [65]. These nucleic acids include immunostimulatory DNA/RNA, genome editing nucleic acids, and mRNA/plasmid, which can be further translated to immunotherapeutic proteins [66]. In addition, different genetic tools such as gene editing, gene silencing, or gene activating systems are also being studied extensively in cancer immunotherapy [65]. Nonetheless, despite the tremendous potential of nucleic acids in cancer immunotherapy, the major limitation in the implementation of these techniques in clinical practice is the lack of an efficient delivery vehicle targeted to the cancer cells. In this context, albumin-based nanocarriers are being investigated in a variety of cancers. For instance, Cheng and co-workers developed HSA NPs complexed with stearyl PEI (stPEI), which was non-covalently bound to plasmid (CRISPR/Cas9) and a siRNA that silenced the expression of programmed cell death ligand-1 (PD-L1) for cancer immunotherapy [46]. This combined approach produced a synergistic effect where the PD-L1 expression was inhibited by 21.2%.
In summary, immunotherapy against cancer mediated by nucleic acids has enormous potential, as highlighted by the recent developments, such as chimeric antigen receptors (CARs), to treat leukemia (e.g., Kymriah [67]), or CRISPR/Cas9 approaches employed to enhance T-cell mediated gene therapy [68]. However, such systems can be further improved by nanocarriers, such as those based on albumin.

6. Conclusion

In conclusion, albumin nanocarriers have been studied widely for gene therapy in cancer because of the unique features of albumin, such as the ease of preparation, high stability, and biocompatibility. Furthermore, the surface of those nanocarriers can be modified to enhance the therapeutic efficiency and selectivity, whereas reducing the undesired off-target effects. Despite all those features, some limitations are still being reported and need to be addressed properly, such as the albumin catabolism, which may be affected by various factors such as the levels of corticosteroids. Therefore, further studies are required to ensure the safe use of those nanocarriers to ease their way to the clinic.

In addition to the prevalent conventional gene therapy, which is mainly focused on the expression of a DNA fragment or its random insertion into the genome, various specific gene-editing tools such as CRISPR/Cas9 have been introduced. These gene-editing tools have promising potential for the introduction of personalized medicines in cancer therapy. In a similar way, novel nucleic acid-based therapies such as chimeric antigen receptor (CAR) T approaches are being developed as a promising therapeutic approach in immuno-oncology. The combination of the advantages imparted by the albumin-based nanocarriers with powerful therapies including CRISPR/Cas9 and CAR-T will revolutionize the treatment options in oncology. Though there are limited studies available on the incorporation of these gene-editing tools in albumin nanostructures, the profound therapeutic application of these vectors is on the near horizon.


  1. Fitzmaurice, C.; Allen, C.; Barber, R.M.; Barregard, L.; Bhutta, Z.A.; Brenner, H.; Dicker, D.J.; Chimed-Orchir, O.; Dandona, R.; Dandona, L.; et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 2017, 3, 524–548.
  2. Siegel, R.L.; Miller, K.D.; Jemal, D.A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30.
  3. Sawyers, C.L. Targeted cancer therapy. Nature 2004, 432, 294–297.
  4. Patil, P.M.; Chaudhari, P.D.; Sahu, M.; Duragkar, N.J. Review article on gene therapy. Int. J. Genet. 2012, 4, 74–79.
  5. Elsabahy, M.; Nazarali, A.; Foldvari, M. Non-viral nucleic acid delivery: Key challenges and future directions. Curr. Drug Deliv. 2011, 8, 235–244.
  6. Silva, A.C.; Lopes, C.M.; Lobo, J.M.S.; Amaral, M.H. Nucleic acids delivery systems: A challenge for pharmaceutical technologists. Curr. Drug Metab. 2015, 16, 3–16.
  7. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751–760.
  8. Jeong, J.H.; Park, T.G.; Kim, S.H. Self-Assembled and Nanostructured siRNA Delivery Systems. Pharm. Res. 2011, 28, 2072–2085.
  9. Gopinath, P.; Kumar, S.U.; Matai, I.; Bhushan, B.; Malwal, D.; Sachdev, A.; Dubey, P. Cancer Nanotheranostics; Springer: Singapore, 2015; ISBN 9789812874351.
  10. Prabhakar, U.; Maeda, H.; Jain, R.K.; Sevick-Muraca, E.M.; Zamboni, W.; Farokhzad, O.C.; Barry, S.T.; Gabizon, A.; Grodzinski, P.; Blakey, D.C. Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology. Cancer Res. 2013, 73, 2412–2417.
  11. Dharap, S.S.; Wang, Y.; Chandna, P.; Khandare, J.J.; Qiu, B.; Gunaseelan, S.; Sinko, P.J.; Stein, S.; Farmanfarmaian, A.; Minko, T.; et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl. Acad. Sci. USA 2005, 102, 12962–12967.
  12. Rothdiener, M.; Beuttler, J.; Messerschmidt, S.K.E.; Kontermann, R.E. Antibody targeting of nanoparticles to tumor-specific receptors: Immunoliposomes. Cancer Nanotechnol. 2010, 1, 295–308.
  13. Wang, C.-H.; Kang, S.-T.; Lee, Y.-H.; Luo, Y.-L.; Huang, Y.-F.; Yeh, C.-K. Aptamer-conjugated and drug-loaded acoustic droplets for ultrasound theranosis. Biomaterials 2012, 33, 1939–1947.
  14. Rosenberg, S.A.; Aebersold, P.; Cornetta, K.; Kasid, A.; Morgan, R.A.; Moen, R.; Karson, E.M.; Lotze, M.T.; Yang, J.C.; Topalian, S.L.; et al. Gene Transfer into Humans—Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction. N. Engl. J. Med. 1990, 323, 570–578.
  15. Alvarez-Salas, L.M. Nucleic acids as therapeutic agents. Curr. Top. Med. Chem. 2008, 8, 1379–1404.
  16. Steinhauser, I.; Langer, K.; Strebhardt, K.; Spänkuch, B. Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression. J. Drug Target. 2009, 17, 627–637.
  17. Li, J.; Wang, Y.; Zhu, Y.; Oupický, D. Recent advances in delivery of drug–nucleic acid combinations for cancer treatment. J. Control. Release 2013, 172, 589–600.
  18. Izquierdo, M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 2005, 12, 217–227.
  19. Shir, A.; Ogris, M.; Wagner, E.; Levitzki, A. EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice. PLoS Med. 2005, 3, e266.
  20. Zhou, G.; Wilson, G.; Hebbard, L.; Duan, W.; Liddle, C.; George, J.; Qiao, L. Aptamers: A promising chemical antibody for cancer therapy. Oncotarget 2016, 7, 13446–13463.
  21. Parsel, S.M.; Grandis, J.R.; Thomas, S.M. Nucleic acid targeting: Towards personalized therapy for head and neck cancer. Oncogene 2016, 35, 3217–3226.
  22. Ramasamy, T.; Munusamy, S.; Ruttala, H.B.; Kim, J.O. Smart Nanocarriers for the Delivery of Nucleic Acid-Based Therapeutics: A Comprehensive Review. Biotechnol. J. 2021, 16, 1900408.
  23. Lu, W.; Sun, Q.; Wan, J.; She, Z.; Jiang, X.-G. Cationic Albumin–Conjugated Pegylated Nanoparticles Allow Gene Delivery into Brain Tumors via Intravenous Administration. Cancer Res. 2006, 66, 11878–11887.
  24. Zhu, Q.; Pan, X.; Sun, Y.; Wang, Z.; Liu, F.; Li, A.; Zhao, Z.; Wang, Y.; Li, K.; Mi, L. Biological nanoparticles carrying the Hmda-7 gene are effective in inhibiting pancreatic cancer in vitro and in vivo. PLoS ONE 2017, 12, e0185507.
  25. Larsen, M.T.; Kuhlmann, M.; Hvam, M.L.; Howard, K.A. Albumin-based drug delivery: Harnessing nature to cure disease. Mol. Cell. Ther. 2016, 4, 3.
  26. Hoogenboezem, E.N.; Duvall, C.L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliv. Rev. 2018, 130, 73–89.
  27. Kragh-Hansen, U.; Chuang, V.T.G.; Otagiri, M. Practical Aspects of the Ligand-Binding and Enzymatic Properties of Human Serum Albumin. Biol. Pharm. Bull. 2002, 25, 695–704.
  28. Quinlan, G.J.; Martin, G.S.; Evans, T.W. Albumin: Biochemical properties and therapeutic potential. Hepatology 2005, 41, 1211–1219.
  29. Merlot, A.M.; Kalinowski, D.S.; Richardson, D.R. Unraveling the mysteries of serum albumin—More than just a serum protein. Front. Physiol. 2014, 5, 299.
  30. Elzoghby, A.O.; Samy, W.M.; Elgindy, N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release 2012, 157, 168–182.
  31. Evans, T.W. Review article: Albumin as a drug—Biological effects of albumin unrelated to oncotic pressure. Aliment. Pharmacol. Ther. 2002, 16, 6–11.
  32. Kratz, F. Albumin, a versatile carrier in oncology. Int. J. Clin. Pharmacol. Ther. 2010, 48, 453–455.
  33. An, F.-F.; Zhang, X.-H. Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery. Theranostics 2017, 7, 3667–3689.
  34. Chatterjee, M.; Ben-Josef, E.; Robb, R.; Vedaie, M.; Seum, S.; Thirumoorthy, K.; Palanichamy, K.; Harbrecht, M.; Chakravarti, A.; Williams, T.M. Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy. Cancer Res. 2017, 77, 5925–5937.
  35. Langer, K.; Anhorn, M.G.; Steinhauser, I.; Dreis, S.; Celebi, D.; Schrickel, N.; Faust, S.; Vogel, V. Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation. Int. J. Pharm. 2008, 347, 109–117.
  36. Karimi, M.; Bahrami, S.; Ravari, S.B.; Zangabad, P.S.; Mirshekari, H.; Bozorgomid, M.; Shahreza, S.; Sori, M.; Hamblin, M.R. Albumin nanostructures as advanced drug delivery systems. Expert Opin. Drug Deliv. 2016, 13, 1609–1623.
  37. Syga, M.-I.; Nicolì, E.; Kohler, E.; Shastri, V.P. Albumin Incorporation in Polyethylenimine–DNA Polyplexes Influences Transfection Efficiency. Biomacromolecules 2016, 17, 200–207.
  38. Rhaese, S.; Von Briesen, H.; Rubsamen-waigmann, H.; Langer, K. Human serum albumin–polyethylenimine nanoparticles for gene delivery. J. Control. Release 2003, 92, 199–208.
  39. Ming, X.; Carver, K.; Wu, L. Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials 2013, 34, 7939–7949.
  40. Wartlick, H.; Spänkuch-Schmitt, B.; Strebhardt, K.; Kreuter, J.; Langer, K. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J. Control. Release 2004, 96, 483–495.
  41. Li, H.; Liu, Y.; Chen, L.; Liu, Q.; Qi, S.; Cheng, X.; Lee, Y.B.; Ahn, C.-H.; Kim, D.J.; Lee, R.J. Folate receptor-targeted lipid-albumin nanoparticles (F-LAN) for therapeutic delivery of an Akt1 antisense oligonucleotide. J. Drug Target. 2018, 26, 466–473.
  42. Son, S.; Song, S.; Lee, S.J.; Min, S.; Kim, S.A.; Yhee, J.Y.; Huh, M.S.; Kwon, I.C.; Jeong, S.Y.; Byun, Y.; et al. Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors. Biomaterials 2013, 34, 9475–9485.
  43. Choi, J.-H.; Hwang, H.-J.; Shin, S.W.; Choi, J.-W.; Um, S.H.; Oh, B.-K. A novel albumin nanocomplex containing both small interfering RNA and gold nanorods for synergetic anticancer therapy. Nanoscale 2015, 7, 9229–9237.
  44. Piao, L.; Li, H.; Teng, L.; Yung, B.C.; Sugimoto, Y.; Brueggemeier, R.W.; Lee, R.J. Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomed. Nanotechnol. Biol. Med. 2013, 9, 122–129.
  45. Zhu, G.; Lynn, G.M.; Jacobson, O.; Chen, K.; Liu, Y.; Zhang, H.; Ma, Y.; Zhang, F.; Tian, R.; Ni, Q.; et al. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat. Commun. 2017, 8, 1–15.
  46. Cheng, W.; Sheu, M.; Lin, H. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy. Int. J. Nanomed. 2018, 13, 7079–7094.
  47. Yedomon, B.H.; Fessi, H.; Charcosset, C. Preparation of Bovine Serum Albumin (BSA) nanoparticles by desolvation using a membrane contactor: A new tool for large scale production. Eur. J. Pharm. Biopharm. 2013, 85, 398–405.
  48. Mo, Y.; Barnett, M.E.; Takemoto, D.; Davidson, H.; Kompella, U.B. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol. Vis. 2007, 13, 746–757.
  49. Wagh, J.; Patel, K.J.; Soni, P.; Desai, K.; Upadhyay, P.; Soni, H.P. Transfecting pDNA to E. coli DH5α using bovine serum albumin nanoparticles as a delivery vehicle. Luminescence 2015, 30, 583–591.
  50. Hall, A.; Lächelt, U.; Bartek, J.; Wagner, E.; Moghimi, S.M. Polyplex Evolution: Understanding Biology, Optimizing Performance. Mol. Ther. 2017, 25, 1476–1490.
  51. Boussif, O.; Lezoualc’H, F.; Zanta, M.A.; Mergny, M.D.; Scherman, D.; Demeneix, B.; Behr, J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. USA 1995, 92, 7297–7301.
  52. Kumari, M.; Liu, C.-H.; Wu, W.-C. Efficient gene delivery by oligochitosan conjugated serum albumin: Facile synthesis, polyplex stability, and transfection. Carbohydr. Polym. 2018, 183, 37–49.
  53. Nicolì, E.; Syga, M.I.; Bosetti, M.; Shastri, V.P. Enhanced Gene Silencing through Human Serum Albumin-Mediated Delivery of Polyethylenimine-siRNA Polyplexes. PLoS ONE 2015, 10, e0122581.
  54. Kudarha, R.R.; Sawant, K.K. Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches. Mater. Sci. Eng. C 2017, 81, 607–626.
  55. Kang, H.; Alam, R.; Dixit, V.; Fisher, M.; Juliano, R.L. Cellular Delivery and Biological Activity of Antisense Oligonucleotides Conjugated to a Targeted Protein Carrier. Bioconjug. Chem. 2008, 19, 2182–2188.
  56. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387–6392.
  57. Carver, K.; Ming, X.; Juliano, R.L. Multicellular Tumor Spheroids as a Model for Assessing Delivery of Oligonucleotides in Three Dimensions. Mol. Ther. Nucleic Acids 2014, 3, e153.
  58. Sarett, S.M.; Werfel, T.A.; Lee, L.; Jackson, M.A.; Kilchrist, K.V.; Brantley-Sieders, D.; Duvall, C.L. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Proc. Natl. Acad. Sci. USA 2017, 114, E6490–E6497.
  59. Boisguérin, P.; Konate, K.; Josse, E.; Vivès, E.; Deshayes, S. Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery. Biomedicines 2021, 9, 583.
  60. Ghahremani, F.; Shahbazi-Gahrouei, D.; Kefayat, A.; Motaghi, H.; Mehrgardi, M.A.; Javanmard, S.H. AS1411 aptamer conjugated gold nanoclusters as a targeted radiosensitizer for megavoltage radiation therapy of 4T1 breast cancer cells. RSC Adv. 2018, 8, 4249–4258.
  61. Xu, B.; Xu, Y.; Su, G.; Zhu, H.; Zong, L. A multifunctional nanoparticle constructed with a detachable albumin outer shell and a redox-sensitive inner core for efficient siRNA delivery to hepatocellular carcinoma cells. J. Drug Target. 2018, 26, 941–954.
  62. Weecharangsan, W.; Yu, B.; Zheng, Y.; Liu, S.; Pang, J.X.; Lee, L.J.; Marcucci, G.; Lee, R.J. Efficient Delivery of Antisense Oligodeoxyribonucleotide G3139 by Human Serum Albumin-Coated Liposomes. Mol. Pharm. 2009, 6, 1848–1855.
  63. Kirkwood, J.M.; Butterfield, L.H.; Tarhini, A.A.; Zarour, H.; Kalinski, P.; Ferrone, S. Immunotherapy of cancer in 2012. CA Cancer J. Clin. 2012, 62, 309–335.
  64. Hargadon, K.M.; Johnson, C.E.; Williams, C.J. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 2018, 62, 29–39.
  65. Hager, S.; Fittler, F.J.; Wagner, E.; Bros, M. Nucleic Acid-Based Approaches for Tumor Therapy. Cells 2020, 9, 2061.
  66. Shen, T.; Zhang, Y.; Zhou, S.; Lin, S.; Zhang, X.-B.; Zhu, G. Nucleic Acid Immunotherapeutics for Cancer. ACS Appl. Bio Mater. 2020, 3, 2838–2849.
  67. Fala, L. Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy. Oncol. Guid. FDA Approv. 2018, 11, 37–38.
  68. Rupp, L.J.; Schumann, K.; Roybal, K.T.; Gate, R.E.; Chun, J.Y.; Lim, W.A.; Marson, A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep. 2017, 7, 737.
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : ,
View Times: 551
Revisions: 2 times (View History)
Update Date: 23 Jul 2021